The effect of primary urological cancers on survival in men with secondary prostate cancer
Standard
The effect of primary urological cancers on survival in men with secondary prostate cancer. / Wenzel, Mike; Würnschimmel, Christoph; Nocera, Luigi; Ruvolo, Claudia Collà; Tian, Zhe; Saad, Fred; Briganti, Alberto; Tilki, Derya; Graefen, Markus; Roos, Frederik C; Mandel, Philipp; Chun, Felix K H; Karakiewicz, Pierre I.
in: PROSTATE, Jahrgang 81, Nr. 15, 11.2021, S. 1149-1158.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - The effect of primary urological cancers on survival in men with secondary prostate cancer
AU - Wenzel, Mike
AU - Würnschimmel, Christoph
AU - Nocera, Luigi
AU - Ruvolo, Claudia Collà
AU - Tian, Zhe
AU - Saad, Fred
AU - Briganti, Alberto
AU - Tilki, Derya
AU - Graefen, Markus
AU - Roos, Frederik C
AU - Mandel, Philipp
AU - Chun, Felix K H
AU - Karakiewicz, Pierre I
N1 - © 2021 The Authors. The Prostate published by Wiley Periodicals LLC.
PY - 2021/11
Y1 - 2021/11
N2 - BACKGROUND: To test the effect of urological primary cancers (bladder, kidney, testis, upper tract, penile, urethral) on overall mortality (OM) after secondary prostate cancer (PCa).METHODS: Within the Surveillance, Epidemiology and End Results (SEER) database, patients with urological primary cancers and concomitant secondary PCa (diagnosed 2004-2016) were identified and were matched in 1:4 fashion with primary PCa controls. OM was compared between secondary and primary PCa patients and stratified according to primary urological cancer type, as well as to time interval between primary urological cancer versus secondary PCa diagnoses.RESULTS: We identified 5,987 patients with primary urological and secondary PCa (bladder, n = 3,287; kidney, n = 2,127; testis, n = 391; upper tract, n = 125; penile, n = 47; urethral, n = 10) versus 531,732 primary PCa patients. Except for small proportions of Gleason grade group and age at diagnosis, PCa characteristics between secondary and primary PCa were comparable. Conversely, proportions of secondary PCa patients which received radical prostatectomy were smaller (29.0 vs. 33.5%), while no local treatment rates were higher (34.2 vs. 26.3%). After 1:4 matching, secondary PCa patients exhibited worse OM than primary PCa patients, except for primary testis cancer. Here, no OM differences were recorded. Finally, subgroup analyses showed that the survival disadvantage of secondary PCa patients decreased with longer time interval since primary cancer diagnosis.CONCLUSIONS: After detailed matching for PCa characteristics, secondary PCa patients exhibit worse survival, except for testis cancer patients. The survival disadvantage is attenuated, when secondary PCa diagnosis is made after longer time interval, since primary urological cancer diagnosis.
AB - BACKGROUND: To test the effect of urological primary cancers (bladder, kidney, testis, upper tract, penile, urethral) on overall mortality (OM) after secondary prostate cancer (PCa).METHODS: Within the Surveillance, Epidemiology and End Results (SEER) database, patients with urological primary cancers and concomitant secondary PCa (diagnosed 2004-2016) were identified and were matched in 1:4 fashion with primary PCa controls. OM was compared between secondary and primary PCa patients and stratified according to primary urological cancer type, as well as to time interval between primary urological cancer versus secondary PCa diagnoses.RESULTS: We identified 5,987 patients with primary urological and secondary PCa (bladder, n = 3,287; kidney, n = 2,127; testis, n = 391; upper tract, n = 125; penile, n = 47; urethral, n = 10) versus 531,732 primary PCa patients. Except for small proportions of Gleason grade group and age at diagnosis, PCa characteristics between secondary and primary PCa were comparable. Conversely, proportions of secondary PCa patients which received radical prostatectomy were smaller (29.0 vs. 33.5%), while no local treatment rates were higher (34.2 vs. 26.3%). After 1:4 matching, secondary PCa patients exhibited worse OM than primary PCa patients, except for primary testis cancer. Here, no OM differences were recorded. Finally, subgroup analyses showed that the survival disadvantage of secondary PCa patients decreased with longer time interval since primary cancer diagnosis.CONCLUSIONS: After detailed matching for PCa characteristics, secondary PCa patients exhibit worse survival, except for testis cancer patients. The survival disadvantage is attenuated, when secondary PCa diagnosis is made after longer time interval, since primary urological cancer diagnosis.
U2 - 10.1002/pros.24209
DO - 10.1002/pros.24209
M3 - SCORING: Journal article
C2 - 34402086
VL - 81
SP - 1149
EP - 1158
JO - PROSTATE
JF - PROSTATE
SN - 0270-4137
IS - 15
ER -